Sirolimus and Its Effects on Restenosis
Author Information
Author(s): Rainer Voisard, Svenja Zellmann, Fabian Müller, Felicitas Fahlisch, Lutz von Müller, Regine Baur, Jürgen Braun, Jürgen Gschwendt, Margaratis Kountides, Vinzenz Hombach, Joachim Kamenz
Primary Institution: University of Ulm
Hypothesis
What are the effects of sirolimus on key events of restenosis in human in vitro and ex vivo models?
Conclusion
Sirolimus significantly inhibits key events of restenosis, including ICAM-1 expression, cell migration, and cell proliferation.
Supporting Evidence
- Sirolimus significantly inhibited ICAM-1 expression in human coronary endothelial and smooth muscle cells.
- Cell migration of human coronary smooth muscle cells was significantly inhibited by sirolimus.
- Cell proliferation and neointimal hyperplasia were inhibited at day 21 and day 56 after treatment with sirolimus.
Takeaway
Sirolimus is a medicine that helps stop blood vessels from getting blocked again after they have been treated. It works by stopping certain cells from growing too much.
Methodology
The study used human in vitro and ex vivo models to assess the effects of sirolimus on cell proliferation, apoptosis, and neointimal hyperplasia.
Potential Biases
High standard deviations in ex vivo models due to preparation procedures may affect results.
Limitations
The study focused only on ICAM-1 expression and did not consider other inflammation markers.
Participant Demographics
15 patients, ages 66.5 ± 10 years, 11 males and 4 females.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.01
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website